8-KRegulation FD

Elevance Health, Inc. 8-K Report, Regulation FD Disclosure (Mar 8, 2022)

Filed March 8, 2022For Securities:ELV

Summary

Elevance Health, Inc. (formerly Anthem, Inc.) filed an 8-K on March 8, 2022, primarily to reaffirm its financial guidance for the full year 2022. The company expects net income to be greater than $26.75 per share, which includes approximately $1.50 per share in net unfavorable items. Excluding these specific items, the adjusted net income guidance remains strong, projected to be greater than $28.25 per share. This reaffirmation comes as company officers are scheduled to engage with investors over the coming weeks. While the filing does not introduce new operational developments, it serves to reinforce management's confidence in the company's financial trajectory for the year. Investors should note that the information provided is subject to forward-looking statement disclaimers and potential risks outlined in the company's other SEC filings.

Key Highlights

  • 1Elevance Health reaffirms its 2022 full-year net income guidance.
  • 2Projected net income for FY2022 is greater than $26.75 per share.
  • 3Includes approximately $1.50 per share in expected net unfavorable items.
  • 4Excluding unfavorable items, adjusted net income guidance is greater than $28.25 per share.
  • 5The company's officers will be speaking with investors in the coming weeks.
  • 6The filing is made under Regulation FD Disclosure (Item 7.01).
  • 7Information furnished is not deemed 'filed' for Section 18 purposes.

Frequently Asked Questions

The main purpose of this 8-K filing is to reaffirm Elevance Health's financial guidance for the full year 2022 and to inform investors that company officers will be meeting with them in the upcoming weeks to discuss this guidance and other company matters.

Elevance Health expects its net income for the full year 2022 to be greater than $26.75 per share. After accounting for approximately $1.50 per share of net unfavorable items, the company projects an adjusted net income greater than $28.25 per share.

No, this 8-K filing, specifically under Item 7.01 Regulation FD Disclosure, does not contain new business updates, acquisitions, or operational changes. It solely focuses on reaffirming financial guidance and informing investors about upcoming discussions.

Investors should be aware that the filing contains forward-looking statements that are subject to risks and uncertainties. These statements reflect management's current views on future events and financial performance, but actual results could differ materially due to various factors, including those detailed in Elevance Health's other SEC filings.